SCHEDULE: Paulson & Co. Discloses 6.1% Stake in Madrigal Pharma
Schedule 13G Amendment
Paulson & Co. Inc. has filed a Schedule 13G reporting beneficial ownership of 6.1% of Madrigal Pharmaceuticals, Inc. common stock.
Summary
- Paulson & Co. Inc. reported ownership of 1,392,188 shares of Madrigal Pharmaceuticals, Inc. common stock.
- This holding represents 6.1% of the total outstanding shares of the company.
- The filing is an Amendment No. 4 to the original Schedule 13G.
- The reporting person acts as an investment adviser and manages these shares on behalf of various investment funds and accounts.
- Paulson & Co. Inc. disclaims beneficial ownership of the reported securities.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral regulatory disclosure confirming institutional interest without indicating any change in corporate strategy or operational performance.
Positives
- Institutional investor confidence indicated by a significant 6.1% stake in the company.
Negatives
- None identified in this ownership disclosure filing.
Risks
- The investment is held for passive investment purposes, meaning the firm does not intend to influence or change the control of the issuer.
Future Outlook
The filing states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
StockSavvy.ai notes that institutional 13G filings are standard disclosures for investment firms managing client assets and typically signal long-term portfolio positioning rather than activist intent in the biotechnology sector.
Comparison to Industry Standards
- The filing follows standard SEC regulatory requirements for institutional investment managers holding over 5% of a public company's equity.
- The passive nature of the holding is consistent with typical hedge fund portfolio management strategies for mid-cap biotech stocks.
Stakeholder Impact
- Shareholders may view the continued presence of a major institutional investor as a sign of stability.
Next Steps
- Continued monitoring of institutional ownership changes in Madrigal Pharmaceuticals.
Key Dates
| Date | Description |
|---|---|
| 02/12/2026 | Date used for total shares outstanding calculation. |
| 02/19/2026 | Date of the Issuer's Annual Report on Form 10-K. |
| 03/31/2026 | Date of the event which requires the filing of this statement. |
| 05/15/2026 | Date of the filing signature. |
Keywords
Madrigal Pharmaceuticals, Paulson & Co, Schedule 13G, Institutional Ownership, MDGL, Biotech Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.